Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931237 | 0.86 | TRPV3 (0.48) | TRPV3JAK2JAK1HPGDSPRMT5 | |
| SCHEMBL14541612 | 0.85 | TRPV3 (0.45) | TRPV3JAK2JAK1HPGDSPRMT5 | |
| SCHEMBL11931257 | 0.84 | CHEK1 (0.50) | TRPV3JAK2JAK1HPGDSPRMT5 | |
| SCHEMBL11931256 | 0.84 | TRPV3 (0.45) | TRPV3JAK2JAK1HPGDSPRMT5 | |
| SCHEMBL14050952 | 0.83 | TRPV3 (0.46) | TRPV3JAK2JAK1HPGDSPRMT5 | |
| SCHEMBL14050868 | 0.83 | TRPV3 (0.43) | TRPV3JAK2JAK1HPGDSPRMT5 | |
| SCHEMBL593570 | 0.81 | TRPV3 (0.47) | TRPV3HPGDSUSP30GPR119CCNK | |
| SCHEMBL2679959 | 0.79 | CHEK1 (0.48) | TRPV3HPGDSUSP30GPR119CCNK | |
| SCHEMBL594178 | 0.79 | GPR119 (0.45) | TRPV3USP30GPR119CCNKCDK12 | |
| SCHEMBL11931347 | 0.79 | CHEK1 (0.51) | USP30IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069349-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7605155-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605155-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2008045267-A2 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | TRPV3 4249/4885JAK2 400/4885JAK1 141/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | TRPV3 4249/4885JAK2 400/4885JAK1 141/4885 |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | TRPV3 4323/4885JAK2 254/4885JAK1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.